

Reyhane Chamani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4865966/publications.pdf>

Version: 2024-02-01

8
papers

44
citations

2258059

3
h-index

2053705

5
g-index

8
all docs

8
docs citations

8
times ranked

67
citing authors

#	ARTICLE	IF	CITATIONS
1	New insights into short peptides derived from the collagen NC1 $\hat{1}\pm 1$, $\hat{1}\pm 2$, and $\hat{1}\pm 3$ (IV) domains: An experimental and MD simulations study. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2022, 1870, 140769.	2.3	3
2	Mutational Analysis of the VPREB1 Gene of Pre-BCR Complex in a Cohort of Sporadic Pediatric Patients With B-Cell Acute Lymphoblastic Leukemia. <i>Journal of Pediatric Hematology/Oncology</i> , 2022, Publish Ahead of Print, .	0.6	0
3	Mutational and bioinformatics analysis of the NKX2.1 gene in a cohort of Iranian pediatric patients with congenital hypothyroidism (CH). <i>Physiology International</i> , 2022, 109, 261-277.	1.6	0
4	Re-engineering of the Immunosuppressive Tumor Microenvironment by Antiangiogenic Therapy. <i>International Journal of Peptide Research and Therapeutics</i> , 2020, 26, 539-546.	1.9	1
5	Application of E75 peptide vaccine in breast cancer patients: A systematic review and meta-analysis. <i>European Journal of Pharmacology</i> , 2018, 831, 87-93.	3.5	19
6	The antiangiogenic and antitumor activities of the N-terminal fragment of endostatin augmented by Ile/Arg substitution: The overall structure implicated the biological activity. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2016, 1864, 1765-1774.	2.3	9
7	Engineering of a disulfide loop instead of a Zn binding loop restores the anti-proliferative, anti-angiogenic and anti-tumor activities of the N-terminal fragment of endostatin: Mechanistic and therapeutic insights. <i>Vascular Pharmacology</i> , 2015, 72, 73-82.	2.1	12
8	In-silico study to identify the pathogenic single nucleotide polymorphisms in the coding region of CDKN2A gene. <i>Iranian Journal of Pediatric Hematology and Oncology</i> , 0, , .	0.4	0